In this new role, Chowrira will work as a close partner to PureTech’s Chief Executive on strategy, corporate and business development, and value realization across PureTech Health’s pipeline.
“We are thrilled to have Bharatt join PureTech Health and bring his diverse experience and deal-making track record to our team as we rapidly approach key value-driving milestones,” said Daphne Zohar, Chief Executive Officer of PureTech Health.
“PureTech Health has an all-star team and an exciting, advanced pipeline which I believe has tremendous value,” said Chowrira.
“I look forward to working closely with Daphne and other members of this exceptional team and prestigious board to realise some of this value and raise the profile of the company with a broader group of investors and analysts.”
“This is an exciting time to join one of the most innovative companies in healthcare and biotech.”
Chowrira joins PureTech Health with more than two decades of experience in the biopharma industry, combining a unique blend of R and D, corporate development, operations, financing, public offering, M and A, legal, IP, and licensing expertise.
He was most recently the President of Synlogic, where he oversaw and managed corporate and business development, alliance management, financial, HR, IP, and legal operations.
Prior to joining Synlogic, Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals.
He was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly-traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar, Merck, Sirna and Ribozyme.
Chowrira also serves on the board of Critical Outcome Technologies. He has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, an M.S. in Molecular Biology from Illinois State University and a B.S. in Microbiology from the UAS, Bangalore, India.